Jornay PM (methylphenidate hydrochloride) for ADHD in children with epilepsy

You may qualify if

• Established diagnosis of epilepsy that requires treatment with anti-seizure medication.
• No episodes of seizure clusters or status epilepticus within 30 days prior to entry into the study.
• Diagnosis of ADHD with functional impairment.
• Good general health as determined by medical history and physical examination, including stable vital signs.
• Participant or legal caregiver capable of providing informed consent and fully capable of monitoring the subject's disease process and compliance with treatment.

You can't join if

• Previous allergic or hypersensitivity reactions to stimulant medicines including Jornay PM®
• Active substance abuse or dependence within 30 days of enrollment
• Epilepsy that is unstable or with seizure frequency that exceeds four events per month, based on an average over the previous three months
• DSM-V diagnosis of psychotic illness or imminent risk of harm to self or others.
• Current use of stimulants to treat ADHD
• Serious or unstable medical or neurologic conditions such as HIV, liver or kidney disease, cancer or diabetes.
• Unstable cardiac illness such as arrythmias or cardiomyopathy.
• Participation in a previous experimental drug study within 30 days of baseline visit.
• Estimated IQ<70 as indicated by clinical assessment to the degree that rating scales may be invalid
• Insufficient capacity of caregiver or legal guardian to understand and appropriately consent for study procedures